Safety and Immunogenicity of a Recombinant Tetravalent Dengue Vaccine in 9–16 Year Olds
- 1 October 2013
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in The Pediatric Infectious Disease Journal
- Vol. 32 (10), 1102-1109
- https://doi.org/10.1097/inf.0b013e31829b8022
Abstract
The dengue virus is a member of the Flavivirus (FV) genus, which also includes the yellow fever virus. Dengue disease is caused by any 1 of 4 dengue virus serotypes and is a serious public health concern in Latin America. This study evaluated the safety and immunogenicity of a candidate recombinant, live-attenuated, tetravalent dengue vaccine (CYD-TDV) in 9-16 year olds in Latin America. In this randomized, blinded, controlled study, volunteers received either 3 doses of CYD-TDV (n = 401) or placebo as first and second injection and tetanus/diphtheria/acellular pertussis vaccine as third injection (n = 199) at 0, 6 and 12 months. Adverse events were documented. Plaque reduction neutralization test antibody titers against the 4 CYD-TDV parental strains were measured before and 28 days after each dose. Seropositivity was defined as antibody titers ≥10 1/dil. The number of adverse reactions decreased after each successive CYD-TDV dose. After each CYD-TDV dose, antibody titers against all 4 serotypes were higher than baseline and respective predose titers. After the third dose of CYD-TDV, 100%, 98.6% and 93.4% of participants were seropositive for at least 2, at least 3 or all 4 serotypes, respectively. Higher antibody titers were observed in participants in the CYD-TDV group who were FV-seropositive at baseline compared with those who were FV-seronegative. CYD-TDV had a favorable safety profile and elicited antibody responses against all 4 dengue virus serotypes in 9-16 year olds in Latin America. These findings support the continued development of CYD-TDV.Keywords
This publication has 21 references indexed in Scilit:
- Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2–45 yearsHuman Vaccines & Immunotherapeutics, 2012
- Flavivirus-induced antibody cross-reactivityJournal of General Virology, 2011
- Priming Effect of Dengue and Yellow Fever Vaccination on the Immunogenicity, Infectivity, and Safety of a Tetravalent Dengue Vaccine in HumansThe American Journal of Tropical Medicine and Hygiene, 2011
- From research to phase III: Preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccineVaccine, 2011
- Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: Randomized controlled phase I trial in the PhilippinesVaccine, 2011
- Early diagnosis of dengue in travelers: Comparison of a novel real-time RT-PCR, NS1 antigen detection and serologyJournal of Clinical Virology, 2010
- The Epidemiology of Dengue in the Americas Over the Last Three Decades: A Worrisome RealityThe American Journal of Tropical Medicine and Hygiene, 2010
- Short communication: Impact of climate variability on the incidence of dengue in MexicoTropical Medicine & International Health, 2007
- Live Attenuated Chimeric Yellow Fever Dengue Type 2 (ChimeriVax™-DEN2) Vaccine: Phase I Clinical Trial for Safety and Immunogenicity: Effect of Yellow Fever Pre-immunity in Induction of Cross Neutralizing Antibody Responses to AllHuman Vaccines, 2006
- Laboratory Testing for West Nile VirusAnnals of the New York Academy of Sciences, 2006